Vertex Pharmaceuticals (NQ:VRTX)

Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026 ↗

Today 9:50 EST

It could be another tough year for the once-soaring drugmaker.

Date: January 7, 2026 Introduction Moderna, Inc. (NASDAQ: MRNA), once the definitive poster child of the COVID-19 pandemic response, is currently undergoing one of the most significant pivots in the...

Topics Intellectual Property

Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge

January 07, 2026

Via PredictStreet

Topics Economy Initial Public Offering Intellectual Property

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Compelling Value Stock Candidate ↗

January 01, 2026

Via Chartmill

Stocks making big moves yesterday: Herbalife, Vertex Pharmaceuticals, Micron, Amkor, and Palantir Technologies

January 07, 2026

Check out the companies making headlines yesterday:

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 3.8% in the afternoon session after Wolfe Research upgraded the stock from "Peer Perform" to "Outperform" and issued a $548 price...

Topics Artificial Intelligence

Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why

January 06, 2026

Investing in a few of these players could increase the diversification of your portfolio.

My 10 Top Stocks to Buy to Start the New Year Off Right ↗

January 05, 2026

BofA Unveils Q1 2026 Top Stock Picks: High-Conviction Bets on AI Infrastructure and Health Care Valuations

Topics Artificial Intelligence

January 02, 2026

As the opening bells of 2026 ring across Wall Street, Bank of America Securities has released its highly anticipated "Top 10 U.S. Stock Ideas for Q1 2026." The report, a cornerstone for institutional...

These three stocks could make 2026 a happy new year for investors.

Topics Artificial Intelligence Economy

The Best Stocks to Invest $1,000 in to Start the New Year Off Right ↗

January 01, 2026

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Topics Artificial Intelligence

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.

Topics Artificial Intelligence ETFs Economy

Stay informed with the top movers within the S&P500 index on Tuesday. ↗

December 30, 2025

Via Chartmill

Discover which S&P500 stocks are making waves on Tuesday. ↗

December 30, 2025

Via Chartmill

2 Growth Stocks to Buy For 2026 and Beyond ↗

December 30, 2025

Neither had a great year in 2025, but the future is looking bright.

The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or...

Topics Economy

2 Nasdaq 100 Stocks Worth Investigating and 1 We Turn Down

December 28, 2025

Growth stocks fall in and out of favor with investors, but quality businesses are always worth buying.

Topics Electric Vehicles World Trade

3 Supercharged Growth Stocks to Buy and Hold Into the 2030s ↗

December 28, 2025

This stock is a great choice for cautious and aggressive investors.

Topics Artificial Intelligence

Forget Moderna Stock, This is a Much Better Buy ↗

December 27, 2025

The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy

Topics Intellectual Property

December 24, 2025

On December 23, 2025, the biotechnology landscape shifted for thousands of patients living with chronic anemia. The U.S. Food and Drug Administration (FDA) granted approval to AQVESME (mitapivat),...

Via PredictStreet

Topics Economy

Is CRISPR Therapeutics Stock Yesterday's News? ↗

December 24, 2025

The biotech sells blood disorders treatment, Casgevy.

As of December 22, 2025, Moderna, Inc. (NASDAQ: MRNA) stands at a critical juncture in its corporate evolution. Once the poster child for the biotechnology industry’s rapid response to the global...

Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive

December 22, 2025

Via PredictStreet

Topics Earnings Initial Public Offering Intellectual Property

Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A GARP Case Study in Affordable Growth ↗

December 22, 2025

Vertex Pharmaceuticals (VRTX) exemplifies GARP investing, offering strong earnings growth, top profitability, and a debt-free balance sheet at a reasonable market valuation.

Via Chartmill

2 Cash-Producing Stocks to Consider Right Now and 1 We Find Risky

December 21, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Next year could be crucial for the company as sales for its only approved treatment could take off.

Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? ↗

December 19, 2025

Since June 2025, Vertex Pharmaceuticals has been in a holding pattern, posting a small return of 0.5% while floating around $450.68. The stock also fell short of the S&P 500’s 13.6% gain during that...

2 Reasons to Watch VRTX and 1 to Stay Cautious

December 17, 2025

The following players span a variety of industries, so if you pick up more than one, you may gain in diversification.

Topics Stocks

12 Days of Investing: My Top 12 Stocks to Buy Before 2026 ↗

December 15, 2025

Vertex Pharmaceuticals (NASDAQ:VRTX) Combines Strong Growth with Technical Breakout Potential ↗

Topics Artificial Intelligence

December 15, 2025

Vertex Pharmaceuticals (VRTX) shows strong growth fundamentals and a positive technical breakout setup, combining high earnings forecasts with a promising stock chart pattern.

Via Chartmill

2 Healthcare Stocks to Buy Ahead of the New Year ↗

December 12, 2025

These companies could innovate their way to success.

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth...

1 Large-Cap Stock to Consider Right Now and 2 Facing Challenges

December 08, 2025

As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock...

Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth

December 11, 2025

The stock has fallen from a peak back in April.

Topics Artificial Intelligence Economy Emissions

Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals? ↗

December 06, 2025

The stock has climbed in the double-digits in recent years.

1 Reason I'll Never Sell Vertex Pharmaceuticals Stock ↗

December 04, 2025